1 / 32

HORMONE SENSITIVE/ HORMONE RESISTANT PROSTATE CANCER

HORMONE SENSITIVE/ HORMONE RESISTANT PROSTATE CANCER. Daniel H Shevrin, MD Hematology/Oncology Northshore University HealthSystem. DISCLOSURES. Consultant: Astella, Novartis, Astra Zeneca, Orion Speakers Bureau: Novartis, Sanofi-Aventis

christy
Download Presentation

HORMONE SENSITIVE/ HORMONE RESISTANT PROSTATE CANCER

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HORMONE SENSITIVE/HORMONE RESISTANTPROSTATE CANCER Daniel H Shevrin, MD Hematology/Oncology Northshore University HealthSystem

  2. DISCLOSURES • Consultant: Astella, Novartis, Astra Zeneca, Orion • Speakers Bureau: Novartis, Sanofi-Aventis • Grant/Research Support: Genentech, GSK, NIH, DOD, ECOG

  3. ADVANCED/RECURRENT PROSTATE CANCER - GENERAL CONCEPTS • Natural history is variable and can be very long • PSA kinetics helpful • Androgen ablation therapy (AAT) remains mainstay of therapy • Androgen receptor remains relevant throughout tumor progression, ie further androgen ablative therapies useful even after initial progression • Immune therapy (Provenge) has a role • Taxotere plays major role in symptomatic disease • New therapies becoming available after Taxotere progression

  4. Death 34,000 ABI Chemo MDV-3100 CRPC Hormonal Management 5-10 years Metastatic 2-3 years Locally Advanced 3-5 years Fail Local Treatment (30%) Local Therapy Incidence 240,000 10,000,000 men at risk

  5. Androgen Ablation

  6. Endocrine Axis in Prostate Cancer GnRH agonist Adrenal Blockade Orchiectomy Tumor Androgens Antiandrogens

  7. ANDROGEN ABLATION – FIRST LINE TREATMENT • Surgical orchiectomy • LHRH agonist • Lupron • Zoladex • Casodex used first month to prevent flare • Casodex can be used as combined therapy • LHRH antagonist - Degaralix (Firmagon) • No flare

  8. ANDROGEN ABLATION – SECOND LINE TREATMENT Anti-androgens Casodex® Flutamide® Nilutamide® Anti-androgen withdrawal Ketoconazole 17,20-lyase inhibitors (Zytiga, TAK-700)

  9. Ketoconazole Inhibits cytochrome P-450 enzymes Blocks testicular and adrenal androgenesis 200 - 400 mg TID Acid environment improves absorption Replacement hydrocortisone required PSA response rate  40% Nausea, LFT abnormalities, rash (rare) Drug interactions – statins, coumadin, BP meds

  10. HORMONE-SENSITIVE PC • The androgen receptor (AR) is the most important target in prostate cancer • Initial lowering of testosterone (T) targets AR and is effective > 90% time • Cells that are “sensitive”, ie require normal levels of testosterone will die • PSA always declines (often to undetectable) • Clinical response is seen (tumor shrinkage, pain improves) • Side-effects develop from lowering of T • Treatment is not curative – some cells do not die and grow in spite of low T levels

  11. SIDE-EFFECTS OF AAT • Hot flashes – effexor, megace • Loss of libido/ED – sexual rehab • Weight gain – diet, exercise • Muscle weakness - exercise • Loss of bone density – DEXA, Ca/D, bisphos • Cardiovascular effects – PCP, cardiologist • Glucose/Insulin effects – PCP, diet • Cognitive effects – neuro consult

  12. Intermittent vs. Continuous Fixed on-phase (6-8 months) of ADT Variable off-phase depends on recovery of testosterone and biologic behavior of cancer Must monitor T and PSA levels and clinical status Data for less bone density loss Suggestion of improved sexual function and QOL Intermittent therapy better tolerated and not associated with worse outcome Intermittent therapy is a reasonable option for patients requiring androgen deprivation

  13. HORMONE-RESISTANT PC • The androgen receptor remains critical even in the hormone-resistant state • Some cells can grow even with exceedingly low levels of Testosterone • Various mechanisms to achieve this (see diagram) • Treatment goal is to further target AR by depriving it of as much T as possible

  14. . Scher H I et al. JCO 2008;26:1148-1159 ©2008 by American Society of Clinical Oncology

  15. CASTRATE-SENSITIVE, NON-METASTATIC • Rising PSA after primary therapy • Biochemical recurrence • Stage D0 • If prostatectomy, consider XRT • PSA doubling time predictor of risk for metastasis • PSADT < 12 months • Androgen ablation therapy standard of care • Data supporting intermittent therapy • Clinical trials

  16. CASTRATE-SENSITIVE, METASTATIC • Metastasis typically bone and nodes • Wide variation in natural history • Depends on extent of osseous mets • Presence of visceral mets • Grade of tumor • PSADT • Good risk • Time to progression 3-5+ years • Poor risk • Time to progression 1-3 years • Standard of care is AAT • Evidence supporting intermittent AAT

  17. CASTRATE-RESISTANT, NON-METASTATIC • Defined as rising PSA on LHRH therapy • Castrate testosterone level • Negative scans • No symptoms of disease • Variable natural history • Time to metastasis 1-3+ years • PSADT helpful - < 9 months predicts mets within 2 years • Treatment is second-line AAT • Antiandrogens • Ketoconazole/Zytiga

  18. Castrate Resistant, Metastatic(Pre-Taxotere) Good prognosis (asymptomatic, “low volume”) Standard Taxotere® chemotherapy Antiandrogens, ketoconazole/Zytiga Immunotherapy (Provenge, sipuleucel-T) Investigational therapies Poor prognosis (symptomatic, aggressive) Standard Taxotere® chemotherapy Investigational chemotherapy combinations

  19. CASTRATE-RESISTANT, METASTATIC(Post-Taxotere) • Jevtana (Cabazitaxel) – FDA approved • Zytiga (Abiraterone) – FDA approved • MDV3100 • Other emerging drugs

  20. APPENDICULAR AND AXIAL METASTASIS

  21. Bone Metastases Can Have Serious Consequences

  22. The Cycle of Bone Destruction:Osteoblastic Effects

  23. SKELETAL RELATED EVENTS • SRE • Fracture, need for XRT, cord compression, pain, hypercalcemia • Zometa (Zoledronic acid) • Potent bisphosphonate given IV every 3-4 weeks • Inhibits osteoclasts • 35% reduction in SREs, postponement to time to first SRE • Side-effects (nephrotoxicity, ONJ, flu-like symptoms) • Xgeva (Denosumab) • Rank ligand inhibitor (osteoclast inhibitor) given SQ every 3-4 weeks • Slightly better reduction in SREs and time to first SRE than zometa • Side-effects (hypocalcemia, ONJ) • Both FDA-approved for castrate-resistant, bone mets • ASCO – no superiority of either drug

  24. THANK YOU!

  25. PATIENT CASE • A 68 yo man had T3, PSA 15, grade 8 cancer and underwent XRT and 2 years ADT with PSA going to undetectable. One year after completing ADT, his PSA begins to rise and reaches 2.5 ng/dL in 12 months. He is anxious but asymptomatic. • What term is used to describe his prostate cancer? • What assessment should be done? • Serum testosterone level • Calculate PSA doubling time C) Bone scan • CT ab/pelvis/CXR • All the above (correct answer)

  26. Testosterone level is normal at 190. PSADT is ~6 months. Bone scan and CT scans do not show obvious mets. • What are the correct treatment options? a) Continued monitoring with PSA q 3 months b) Repeat XRT to prostate c) LHRH agonist given continuously or intermittently d) Taxotere chemotherapy e) Casodex alone

  27. Lupron is started every 3 months. PSA falls to 0.4 after 6 months but then rises to 5.5 over next 9 months. Repeat bone scan shows 4 new osseous lesions in the pelvis and spine c/w mets. CT shows enlarged pelvic nodes. He remains asymptomatic other than hot flashes. • What term is used to describe his prostate cancer? • What are the correct treatment options? a) Taxotere chemotherapy b) Add casodex 50 mg/d • Zytiga • Provenge e) Start zometa or xgeva f) b and e (correct)

  28. Casodex is added to Lupron. Zometa is started monthly. PSA continues to rise. He reports mild low back pain relieved with advil. • What are the correct treatment options? a) Another antiandrogen b) Ketoconazole c) Provenge d) Taxotere chemotherapy • Zytiga • b or c (correct)

  29. The pt undergoes treatment with Provenge which is well-tolerated. His PSA continues to rise rapidly. His back pain worsens and is requiring hydrocodone for relief. Scans show 4 new osseous lesions and larger nodes. CT shows new left hydronephrosis. • What are the correct treatment options? a) Referral to Urologist for management of hydro b) XRT to L-spine • Taxotere • All the above (correct)

  30. Urologist stents left ureter. He receives XRT to L-spine with good palliation of pain. He is then treated with Taxotere for 8 cycles with a 50% drop in his PSA. Treatment stopped due to worsening fatigue. His PSA begins to increase within the next 6-7 months. Repeat scans show 3 new bone lesions. • What are the correct treatment options? a) Repeat Taxotere b) Jevtana (Cabazitaxel) • Zytiga (Abiraterone) • Investigational drug • All the above (correct answer)

  31. DISCLOSURES • Consultant: Astella, Novartis, Astra Zeneca, Orion • Speakers Bureau: Novartis, Sanofi-Aventis • Grant/Research Support: Genentech, GSK, NIH, DOD, ECOG

More Related